Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €45.37 EUR
Change Today +0.56 / 1.24%
Volume 74.4K
IPN On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
OTC US
Stuttgart
As of 11:35 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

ipsen (IPN) Snapshot

Open
€44.76
Previous Close
€44.82
Day High
€45.66
Day Low
€44.76
52 Week High
03/3/15 - €46.50
52 Week Low
04/11/14 - €28.24
Market Cap
3.8B
Average Volume 10 Days
113.7K
EPS TTM
€1.68
Shares Outstanding
82.9M
EX-Date
05/29/15
P/E TM
27.0x
Dividend
€0.85
Dividend Yield
1.76%
Current Stock Chart for IPSEN (IPN)

Related News

No related news articles were found.

ipsen (IPN) Related Businessweek News

View More BusinessWeek News

ipsen (IPN) Details

Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Founded in 1929

ipsen (IPN) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: €1.4M
Deputy Chief Executive Officer and Interim Ex...
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2013.

ipsen (IPN) Key Developments

Ipsen S.A. Proposes Payment of Dividend for the Year 2014

The Board of Directors of Ipsen S.A., which met on 2 March 2015, has decided to propose at Ipsen’s annual shareholders’ meeting to be held on 27 May 2015 the payment of a dividend of €0.85 per share, up €0.05 year-on-year, representing a pay-out ratio of approximately 45% of consolidated net profit (attributable to the Group’s shareholders), compared to a pay-out ratio of approximately 44% for the 2013 financial year.

Ipsen S.A. Reports Audited Consolidated Earnings Results for the Year December 31, 2014

Ipsen S.A. reported audited consolidated earnings results for the year December 31, 2014. For the year, the company reported sales of EUR 1,274.8 million against EUR 1,224.8 million a year ago. Total revenues were EUR 1,332.4 million against EUR 1,281.8 million a year ago. Core operating profit was EUR 260.6 million against EUR 228.0 million a year ago. Operating profit was EUR 221.4 million against EUR 210.5 million a year ago. Consolidated net profit was EUR 154.0 million against EUR 153.1 million a year ago. Diluted core EPS was EUR 2.22 against EUR 1.84 a year ago. Profit from continuing operations came to 154.5 million, up 8.6% from 142.2 million at 31 December 2013. Core net profit amounted to EUR 182.6 million, sharply up compared to the EUR 153.7 million recorded at 31 December 2013. Consolidated net profit attributable to shareholders of the company was EUR 153.5 million against EUR 152.5 million a year ago. Net cash flow from operating activities was EUR 246.2 million against EUR 181.4 million a year ago. Net investments in financial and tangible and intangible assets were EUR 84.2 million against EUR 62.3 million a year ago.

Ipsen Appoints Dominique Laymand as Senior Vice President, Chief Ethics and Compliance Officer, Effective March 16, 2015

Ipsen announced that Dominique Laymand has been appointed Senior Vice President, Chief Ethics and Compliance Officer for the Ipsen group, effective as of 16th of March. She will report directly to Marc de Garidel, Chairman and CEO of Ipsen. Dominique Laymand will be a member of the Chairman's Committee. Dominique Laymand was previously Vice President Compliance and Ethics of Bristol Myers Squibb. As such, and since 2004, she set up and managed the compliance and ethics program at BMS for Europe, Middle East, Africa, Turkey and Russia.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPN:FP €45.37 EUR +0.56

IPN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €14.60 EUR +0.09
Meda AB kr136.20 SEK -0.40
Orion Oyj €28.73 EUR +0.13
Procter & Gamble Hygiene & Health Care Ltd 6,990 INR -31.05
Recordati SpA €16.60 EUR +0.01
View Industry Companies
 

Industry Analysis

IPN

Industry Average

Valuation IPN Industry Range
Price/Earnings 21.8x
Price/Sales 2.5x
Price/Book 3.1x
Price/Cash Flow 22.1x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPSEN, please visit www.ipsen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.